Zinc Oxide 100% exempt from Pharmaceutical Tariifs
Filed with ASX · · 1 page · English
Advance ZincTek Limited on 6ix
Earlier from Advance ZincTek
- Appendix 4D
- Chair's Presentation to Shareholders
- Improvement of 26.83% in First Quarter Revenue - FY26
- Appendix 4E
- Response to ASX Price Query
Later from Advance ZincTek
All Advance ZincTek news releasesFollow Advance ZincTek into a list and get an email when it puts out news.
Follow Advance ZincTek